A toxic gas that leaves a residue you have to air out, vs. a beam of radiation that leaves nothing behind except a changed material.
Both are dominant terminal sterilization methods for medical devices, and both reliably achieve the sterility assurance level regulators require. Ethylene oxide (EtO) is a low-temperature gas process: EtO molecules diffuse into and around packaged devices and alkylate microbial DNA, but the gas itself is toxic, flammable, and carcinogenic, so every sterilized load must go through an aeration cycle to purge residual EtO and its reaction byproducts to safe limits before the device can ship. Gamma irradiation uses high-energy photons from a Cobalt-60 source to directly damage microbial DNA — it leaves no chemical residual at all, but the same ionizing energy that kills microorganisms can break polymer chains, and certain materials — most notably ultra-high-molecular-weight polyethylene (UHMWPE) used in joint-replacement bearing surfaces — become measurably more brittle and oxidation-prone after a gamma dose.
EtO sterilization runs at relatively low temperature (typically 30–60°C) and high humidity, which is exactly why it's the go-to method for heat- and moisture-sensitive devices — electronics, catheters with adhesive bonds, complex multi-lumen assemblies — that would be damaged by heat-based or high-energy processes. The tradeoff is cycle time and chemistry: a full EtO cycle including conditioning, gas exposure, and post-sterilization aeration to clear residual ethylene oxide and ethylene chlorohydrin can take days, and the facility itself requires substantial safety infrastructure because EtO is flammable and a known human carcinogen. Gamma irradiation, by contrast, penetrates fully packaged, palletized product in a single continuous exposure with no aeration step and no elevated temperature or humidity requirement — but the absorbed dose (commonly validated around 25 kGy) that reliably kills bioburden is the same dose that scissions polymer chains, so a material's radiation tolerance has to be qualified, not assumed.
Both methods, properly validated, reliably achieve the sterility assurance level of 10⁻⁶ regulators expect — so the choice is rarely about which one sterilizes better. It's about which failure mode the device's specific materials can tolerate. A polyethylene hip liner sterilized by gamma irradiation historically suffered from post-irradiation oxidative degradation that measurably shortened its in-service wear life — a discovery that drove the orthopedic industry toward alternative sterilization (EtO, or gas plasma) or irradiation in an inert or vacuum environment specifically to suppress the oxidative chain reaction. Meanwhile a fully assembled electronic infusion pump with adhesive-bonded subassemblies would be a poor candidate for gamma's ionizing dose but tolerates EtO's low-temperature gas exposure well, provided the aeration cycle is validated long enough to clear residual EtO from its more absorptive materials. Sterilization method selection is therefore a materials-compatibility decision made during device design, not a manufacturing detail bolted on afterward.
EtO kills microorganisms by chemically alkylating their DNA — a reactive gas-phase chemistry that, by the same mechanism, leaves a toxic chemical residual behind that has to be actively purged. Gamma kills microorganisms by directly ionizing and breaking DNA strands with high-energy photons — the same ionizing energy, delivered to a polymer instead of a microorganism, breaks polymer backbone bonds too. Neither downside is an engineering oversight to be fixed; it's the same physical mechanism that provides the sterilizing effect, expressed as a side effect on the device material. That's why the fix is choosing the right method for the material, not trying to eliminate the side effect from a given method.
Gamma removing the residual-chemistry concern doesn't make it universally safer — it trades a chemical-residual risk for a material-degradation risk. A UHMWPE bearing surface embrittled by gamma dose can fail mechanically in service years later, which is arguably a more serious and harder-to-detect risk than a properly validated and aerated EtO residual within regulatory limits. "No residual" describes what gamma leaves in the packaging, not whether the sterilized device itself came through unchanged — those are two different questions, and both matter.
Explains why ethylene oxide (EtO) gas sterilization requires a post-sterilization aeration cycle to clear toxic chemical residual, while gamma irradiation leaves no residual but can degrade radiation-sensitive polymers like UHMWPE through chain scission. Covers why the device's specific materials, not sterility efficacy, typically drive the sterilization method decision.
Both methods are validated to the same sterility assurance level, which invites a false assumption that the choice between them is arbitrary or purely a manufacturing-cost decision. It isn't. EtO's chemical mechanism (alkylating microbial DNA) necessarily leaves a toxic gas residual that must be purged through aeration. Gamma's mechanism (ionizing radiation breaking DNA strands) necessarily risks breaking polymer backbone bonds in materials that share chemical bond structures similar to what's being disrupted in microorganisms. Neither is a flaw unique to one method — each is an unavoidable side effect of the physics or chemistry that makes that method work.
EtO sterilization cycles are validated per ISO 11135, with residual ethylene oxide and ethylene chlorohydrin levels required to fall below specified limits (per ISO 10993-7) before release — aeration time is itself a validated process parameter, not a fixed default. Gamma sterilization is validated per ISO 11137, with absorbed dose (commonly a minimum around 25 kGy, though dose auditing can support lower validated doses) confirmed sufficient for the device's bioburden. Material radiation compatibility is evaluated separately — mechanical property testing before and after irradiation, and sometimes after simulated shelf aging, is used to confirm a given polymer formulation tolerates the validated dose without unacceptable embrittlement or oxidative degradation over the device's shelf life.
Sterilization method should be selected during device design, not left until manufacturing scale-up, because switching sterilization methods late in development can require re-running biocompatibility testing, material characterization, and shelf-life studies from scratch. A device using heat- or radiation-sensitive materials (adhesives, certain electronics, some radiation-sensitive polymers) generally points toward EtO or other low-temperature methods. A device using materials known to have good radiation tolerance, or where cycle time and eliminating residual chemistry concerns matter more, points toward gamma or electron-beam irradiation. Orthopedic bearing surfaces specifically warrant early, explicit sterilization-compatibility testing given UHMWPE's documented radiation sensitivity.
Modern gamma-sterilized UHMWPE implants typically use irradiation in an inert atmosphere (nitrogen or vacuum) rather than air, which substantially suppresses the post-irradiation oxidative chain reaction that caused early-generation degradation problems. Some manufacturers also use highly cross-linked UHMWPE formulations specifically engineered for improved radiation and oxidative stability. So gamma remains viable for these devices, but only with process and material choices specifically engineered around the known degradation mechanism — not the same generic gamma process applied without regard to material sensitivity.
E-beam is a related but distinct ionizing method — it uses accelerated electrons rather than gamma photons from a radioactive source. It shares gamma's core tradeoff (no chemical residual, but ionizing-radiation material effects), but delivers dose much faster and with shallower penetration, making it well suited to lower-density, thinner packaged products. Material compatibility considerations for radiation-sensitive polymers are similar to gamma's, though dose-rate differences can affect degradation kinetics.
In principle a device can be qualified for more than one sterilization method, and some manufacturers do validate a device for two methods to build in supply-chain flexibility. In practice this roughly doubles the validation burden — separate biocompatibility, residual, dose, and material-stability testing for each method — so most programs pick one primary method early based on material compatibility and only pursue a second validated method when there's a specific business reason (sterilization capacity risk, geographic facility availability) to justify the added cost.
Try our Biomedical Engineering
More calculators, simulators, and guides for this discipline.